drugset / Trial / NCT04145570

A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions

NCT04145570

Phase 4 Completed 24 enrolled Quadras Scientific Solutions
RandomizedCrossoverOpen-labelOther

Summary

Theobjectiveofthisstudyistoevaluatethecomparativebioavailabilitybetween: * ErlotinibHCl150mgTablets(Novopharm Limited,Canada)and * Tarceva® 150mgTablets(Hoffmann-LaRocheLimited,Canada) afterasingle-doseinhealthysubjectsunderfastingconditions.

Timeline

Start
2008-10-23
Primary completion
2008-11-09
Completion
2008-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule 150 mg

Indications